Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1260053

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

Schernthaner, Guntram; Karasik, Avraham; Abraitienė, Agnė; Ametov, Alexander S.; Gaàl, Zsolt; Gumprecht, Janusz; Janež, Andrej; Kaser, Susanne; Lalić, Katarina; Mankovsky, Boris N. et al.
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs // Cardiovascular Diabetology, 18 (2019), 1; 115-124 doi:10.1186/s12933-019-0920-3 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1260053 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

Autori
Schernthaner, Guntram ; Karasik, Avraham ; Abraitienė, Agnė ; Ametov, Alexander S. ; Gaàl, Zsolt ; Gumprecht, Janusz ; Janež, Andrej ; Kaser, Susanne ; Lalić, Katarina ; Mankovsky, Boris N. ; Moshkovich, Evgeny ; Past, Marju ; Prázný, Martin ; Radulian, Gabriela ; Smirčić Duvnjak, Lea ; Tkáč, Ivan ; Trušinskis, Kārlis

Izvornik
Cardiovascular Diabetology (1475-2840) 18 (2019), 1; 115-124

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
CVOTs ; EMPA-REG OUTCOME ; EMPRISE ; Heart failure ; Real-world evidence ; Type 2 diabetes.

Sažetak
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.

Izvorni jezik
Engleski



POVEZANOST RADA

Ustanove:
Medicinski fakultet, Zagreb

Profili:

Avatar Url Lea Smirčić-Duvnjak (autor)

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Schernthaner, Guntram; Karasik, Avraham; Abraitienė, Agnė; Ametov, Alexander S.; Gaàl, Zsolt; Gumprecht, Janusz; Janež, Andrej; Kaser, Susanne; Lalić, Katarina; Mankovsky, Boris N. et al.
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs // Cardiovascular Diabetology, 18 (2019), 1; 115-124 doi:10.1186/s12933-019-0920-3 (međunarodna recenzija, članak, znanstveni)
Schernthaner, G., Karasik, A., Abraitienė, A., Ametov, A., Gaàl, Z., Gumprecht, J., Janež, A., Kaser, S., Lalić, K. & Mankovsky, B. (2019) Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. Cardiovascular Diabetology, 18 (1), 115-124 doi:10.1186/s12933-019-0920-3.
@article{article, author = {Schernthaner, Guntram and Karasik, Avraham and Abraitien\.{e}, Agn\.{e} and Ametov, Alexander S. and Ga\`{a}l, Zsolt and Gumprecht, Janusz and Jane\v{z}, Andrej and Kaser, Susanne and Lali\'{c}, Katarina and Mankovsky, Boris N. and Moshkovich, Evgeny and Past, Marju and Pr\'{a}zn\'{y}, Martin and Radulian, Gabriela and Smir\v{c}i\'{c} Duvnjak, Lea and Tk\'{a}\v{c}, Ivan and Tru\v{s}inskis, K\={a}rlis}, year = {2019}, pages = {115-124}, DOI = {10.1186/s12933-019-0920-3}, keywords = {CVOTs, EMPA-REG OUTCOME, EMPRISE, Heart failure, Real-world evidence, Type 2 diabetes.}, journal = {Cardiovascular Diabetology}, doi = {10.1186/s12933-019-0920-3}, volume = {18}, number = {1}, issn = {1475-2840}, title = {Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs}, keyword = {CVOTs, EMPA-REG OUTCOME, EMPRISE, Heart failure, Real-world evidence, Type 2 diabetes.} }
@article{article, author = {Schernthaner, Guntram and Karasik, Avraham and Abraitien\.{e}, Agn\.{e} and Ametov, Alexander S. and Ga\`{a}l, Zsolt and Gumprecht, Janusz and Jane\v{z}, Andrej and Kaser, Susanne and Lali\'{c}, Katarina and Mankovsky, Boris N. and Moshkovich, Evgeny and Past, Marju and Pr\'{a}zn\'{y}, Martin and Radulian, Gabriela and Smir\v{c}i\'{c} Duvnjak, Lea and Tk\'{a}\v{c}, Ivan and Tru\v{s}inskis, K\={a}rlis}, year = {2019}, pages = {115-124}, DOI = {10.1186/s12933-019-0920-3}, keywords = {CVOTs, EMPA-REG OUTCOME, EMPRISE, Heart failure, Real-world evidence, Type 2 diabetes.}, journal = {Cardiovascular Diabetology}, doi = {10.1186/s12933-019-0920-3}, volume = {18}, number = {1}, issn = {1475-2840}, title = {Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs}, keyword = {CVOTs, EMPA-REG OUTCOME, EMPRISE, Heart failure, Real-world evidence, Type 2 diabetes.} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.